INTRODUCTION {#s1}
============

Cancer is a major cause of death in the world, there were 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide \[[@R1]\]. It is well known that earlier diagnosis of cancer can effectively improve prognosis. However, the disease is often clinically silent at an early stage and most tumor biomarkers are not sensitive and specific. Therefore, it is crucial to explore new and efficient biomarkers to predict the prognosis of cancers. Recently, Flotillin-1 protein has considered to be a new prognostic marker for cancers.

Lipid rafts have been reported to be concerned with the development of several malignancies \[[@R2]\]. Therefore, lipid rafts may be a potential therapeutic target formalignant cancers \[[@R3]\]. Flotillin-1, also called reggie-2, is one of the structural proteins of lipid rafts. Flotillin-1 is one member in flotillin proteins family, and it is expressed mostly in brain, lung, placenta and hematopoietic cells \[[@R4], [@R5]\]. The human Flotillin-1 gene was located on chromosome 6p21.3, consisting of 13 exons, and code a protein of 47 kDa \[[@R2]\]. Although Flotillin-1 is universally expressed, its function has not been fully understood. It showed that Flotillin-1 was involved in cellular signal transduction, endocytosis and cell adhesion \[[@R6]--[@R8]\]. Recently, several studies found that Flotillin-1 was closely related to the occurrence and development of tumor \[[@R9]--[@R10]\]. For example, Lin *et al*. revealed that Flotillin-1 was highly expressed in breast cancer specimens, and the high expression level of Flotillin-1 was significantly correlated with later clinical staging and poorer patient survival. In addition, proliferation and tumorigenicity of breast cancer cells would be inhibited by the silence Flotillin-1both *in vitro* and *in vivo* \[[@R9]\]. Therefore, Flotillin-1 plays an important role in the occurrence and development of tumor and may serve as a new prognostic marker for cancer.

Several studies have found that high Flotillin-1 expression was associated with shorter overall survival (OS) and disease-free survival(DFS) in various types of cancer \[[@R9], [@R11]--[@R12]\]. However, the reported prognostic value of Flotillin-1 differed in individual original publications. Until now, there was no systematic study on the prognostic value of Flotillin-1 protein in human tumors. Therefore, this meta-analysis was conducted to investigate the prediction value of elevated Flotillin-1 expression level in solid tumors.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The detailed process of literature retrieval was shown (Figure [1](#F1){ref-type="fig"}). According to above mentioned inclusion and exclusion criteria, a total of 13 studies, published from 2011 to 2016, were finally identified as eligible in this meta-analysis \[[@R9]--[@R21]\]. The main characteristics of all included studies were summarized (Table [1](#T1){ref-type="table"}). There were totally 2473 cancer patients from the People\'s Republic of China \[[@R9]--[@R18]\], Canada \[[@R19]\], Norway \[[@R20]\] and Korea \[[@R21]\]. And the mean patient sample size was 190.2 (ranging from 23 to 432). Nine different kinds of human solid tumors were evaluated in our study, with 3 breast cancer(BC); 1 cervical cancer(CC); 1 esophageal squamous cell carcinoma(ESCC); 1 gastric cancer(GC); 1 hepatocellular carcinoma(HCC); 2 lung carcinoma(LC); 2 renal cell carcinoma(RCC); 1 tongue squamous cell cancer(TSCC) and 1 nasopharyngeal carcinoma(NPC). For the determination of Flotillin-1 expression levels, two assay methods were applied: IHC was applied in 12 studies and WB was applied in 1 study.

![Flowchart presenting the steps of literature retrieval and selection](oncotarget-08-52665-g001){#F1}

###### Main characteristics of studies for association between Flotillin-1expression level and human solid cancers

  Author, year     Country   Cancer type   Total number, patients (n)   Tumor stage (I/II-III/IV)          Adjuvant therapy beforesurgery   Follow-up (months)   Outcome measures/Analysis type   Detection method        High expression
  ---------------- --------- ------------- ---------------------------- ---------------------------------- -------------------------------- -------------------- -------------------------------- ----------------------- ---------------------------------------------------------
  Lin CY, 2011     China     BC            212                          23/97/62/30                        *NA*                             above 60             OS(M)                            IHC                     SI≥4
  Song LB, 2012    China     ESCC          432                          60/194/134/44                      *NA*                             1-120                OS(M)                            IHC                     SI≥4
  Zhang PF, 2012   China     LC            72                           33/6/33 (I/II/III+IV)              NO                               1-60                 OS(M), RFS(M)                    IHC                     A combined staining score (extension + intensity) of ≥5
  Pust S, 2013     Norway    BC            146                          *NA*                               *NA*                             1-60                 DFS(S)                           IHC                     total score (7-8)
  Zhang SH, 2013   China     HCC           196                          18/73/102/3                        *NA*                             median 34.8          OS(M), RFS(S)                    IHC                     SI≥4
  Zhang YY, 2014   China     RCC           182                          98/47/23/14                        *NA*                             above 60             OS(S)                            IHC                     moderate and strong staining (++ or +++)
  Li H, 2014       China     LC            106                          66/40 (I + II/III)                 NO                               1-60                 OS(M)                            IHC                     SI≥4
  Li H, 2014       China     TSCC          181                          82/67/17/15                        NO                               above 60             OS(M), PFS(S)                    IHC                     SI≥6
  Cao CL, 2015     China     GC            157                          68/89 (I + II/III+IV)              NO                               above 60             OS(S), DFS(S)                    IHC                     SI≥4
  Butz H, 2015     Canada    RCC           23                           *NA*                               *NA*                             1-100                OS(S)                            Western blot analysis   *NA*
  Li Z, 2016       China     CC            308                          173/74/28/33 (IB1/IB2/IIA1/IIA2)   NO                               above 60             OS(M), PFS(S)                    IHC                     IRS≥5
  Koh M, 2016      Korea     BC            289                          92/121/51/0                        NO                               median 60            DFS(M)                           IHC                     5% of positive tumor cells with any intensity
  Cao SM, 2016     China     NPC           169                          13/40/67/49                        *NA*                             above 60             OS(M), DFS(S)                    IHC                     SI≥ 8

BC:breast cancer; ESCC:esophageal squamous cell carcinoma; LC:lung carcinoma; HCC:hepatocellular carcinoma;

RCC:renal cell carcinoma; TSCC:tongue squamous cell cancer; NPC:nasopharyngeal carcinoma; CC:cervical cancer;

GC:gastric cancer;

OS:overall survival; RFS:relapse-free survival; DFS:disease-free survival; PFS: progression-free-survival;

IHC:immunohistochemistry; SI:staining index score; IRS: the immunoreactivity score;

(M): Multivariate; (S): Survival curves; *NA*: not available.

High Flotillin-1 expression and overall survival(OS) {#s2_2}
----------------------------------------------------

A total of 11 studies, including 2038 patients, reported the results of OS towards Flotillin-1 protein expression level in cancerous tissues. Nine kinds of solid tumors were involved for OS, with 1 breast cancer(BC); 1 cervical cancer(CC); 1 esophageal squamous cell carcinoma(ESCC); 1 gastric cancer(GC); 1 hepatocellular carcinoma(HCC); 2 lung carcinoma(LC); 2 renal cell carcinoma(RCC); 1 tongue squamous cell cancer(TSCC) and 1 nasopharyngeal carcinoma(NPC). Because no heterogeneity was observed across-studies (I^2^=0%, P~*h*~=0.590), the fixed-effects model was appliedto pool the HRs. Overall, the meta-analysis showed that high Flotillin-1 expression level was significantly associated with shorter OS (HR=1.64; 95%CI:1.39-1.88, p\<0.001) (Figure [2](#F2){ref-type="fig"}). A worse OS was observed in the patients detected with high Flotillin-1 expressionlevel than those of with low Flotillin-1 expression.

![Forest plot of HR for the relationship between high Flotillin-1 expression and OS](oncotarget-08-52665-g002){#F2}

Further, subgroup analyses were performed according tocancer types. The negative effect of elevated Flotillin-1 on OS was revealed in patients with RCC (HR=2.12; 95%CI: 1.45-2.79, p\<0.001) and LC (HR=1.61; 95%CI: 0.89-2.33, p\<0.001), and a similar result was also observed in digestive system cancers (HR=1.47; 95%CI: 1.17-1.77, p\<0.001) (Figure [3](#F3){ref-type="fig"}). In addition, for OS, subgroup analyses were performed according to nationality, detecting method, cutoff value, analysis type, sample size, publication date. In those subgroups, meta-analyses, the calculated pooled HR values were significantly larger than 1.0. (Table [2](#T2){ref-type="table"}, *those figures were presented in [Supplementary Information](#SD1){ref-type="supplementary-material"}*).

![Forest plot of HR for the relationship between high Flotillin-1 expression and OS in various tumors](oncotarget-08-52665-g003){#F3}

###### Pooled hazard ratios for OS according to subgroup analyses

  Categories                    Studies (n)   Number of patients   Fixed-effects model   Heterogeneity         
  ----------------------------- ------------- -------------------- --------------------- --------------- ----- -------
  \[1\]OS                       11            2038                 1.64(1.39-1.88)       \<0.001         0.0   0.590
  \[2\]Nationality                                                                                             
  People\'s Republic of China   10            2015                 1.58(1.31-1.84)       \<0.001         0.0   0.671
  \[3\]Method                                                                                                  
   IHC                          10            2015                 1.58(1.31-1.84)       \<0.001         0.0   0.671
  \[4\]Cutoff value                                                                                            
   SI≥4                         5             1103                 1.49(1.22-1.77)       \<0.001         0.0   0.553
   Others                       6             935                  2.13(1.61-2.64)       \<0.001         0.0   0.970
  \[5\]Analysis type                                                                                           
   Multivariate                 8             1676                 1.53(1.26-1.81)       \<0.001         0.0   0.674
   Non-multivariate             3             362                  2.13(1.54-2.72)       \<0.001         0.0   0.886
  \[6\]Sample size                                                                                             
   ≥ 100                        9             1943                 1.56(1.29-1.83)       \<0.001         0.0   0.622
   \<100                        2             95                   2.06(1.45-2.68)       \<0.001         0.0   0.955
  \[7\]Publication year                                                                                        
   2011-2013                    4             912                  1.49(1.19-1.78)       \<0.001         0.0   0.497
   2014-2016                    7             1126                 1.97(1.53-2.40)       \<0.001         0.0   0.828
  \[8\]Cancer type                                                                                             
   LC                           2             178                  1.61(0.89-2.33)       \<0.001         0.0   0.474
   RCC                          2             205                  2.12(1.45-2.79)       \<0.001         0.0   0.630
   Digestive system cancers     3             785                  1.47(1.17-1.77)       \<0.001         0.0   0.403
   Others                       4             870                  2.23(1.41-3.06)       \<0.001         0.0   0.884

High Flotillin-1 expression and disease-free survival(DFS) {#s2_3}
----------------------------------------------------------

Four studies comprising of 761 patients have investigated the relationship between Flotillin-1 expression level and DFS in cancer patients. Because there was no severe heterogeneity among studies(I^2^= 0%; P~*h*~= 0.840), the fixed-effects model was applied to evaluate the pooled HR with corresponding 95% CI. The pooled result demonstrated a significantly positive association between high Flotillin-1 expression level and poorer DFS (HR = 2.49; 95%CI: 1.64-3.35, p\<0.001) (Figure [4](#F4){ref-type="fig"}).

![Forest plot of HR for the relationship between high Flotillin-1 expression and DFS](oncotarget-08-52665-g004){#F4}

High Flotillin-1 expression and relapse-free survival(RFS) {#s2_4}
----------------------------------------------------------

Two studies comprising of 268 patients have provided available information for RFS analysis. For the heterogeneity detected among studies (I^2^=58.6%, P~*h*~=0.120), the random-effects model was applied to analyze the pooled HR with corresponding 95% CI. Patients with low Flotillin-1 expression might had a better relapse-free survival (HR = 3.26; 95%CI: 1.10-5.43, p= 0.003) (Figure [5](#F5){ref-type="fig"}).

![Forest plot of HR for the relationship between high Flotillin-1 expression and RFS](oncotarget-08-52665-g005){#F5}

High Flotillin-1 expression and progression-free-survival(PFS) {#s2_5}
--------------------------------------------------------------

Two studies reported the association between the Flotillin-1 expression level and PFS. A total of 489 patients was included in this meta-analysis. No significant heterogeneity was observed between studies(I^2^=0%, P~*h*~=0.592), therefore the fixed-effects model was employed to estimate the pooled HR with corresponding 95% CI. The pooled results revealed that there may be a negative correlation between the level of Flotillin-1 protein expression and PFS (HR = 1.84; 95%CI: 0.81-2.87, p\<0.001) (Figure [6](#F6){ref-type="fig"}).

![Forest plot of HR for the relationship between high Flotillin-1 expression and PFS](oncotarget-08-52665-g006){#F6}

High Flotillin-1 expression and clinicopathological parameters {#s2_6}
--------------------------------------------------------------

Meta-analysis indicated that Flotillin-1 expression level was related to histological grade(OR =2.22; 95% CI: 1.04-4.78, p=0.04) and depth of primary tumor invasion(OR =2.73; 95% CI: 1.44-5.17, p=0.002) (Table [3](#T3){ref-type="table"}, *All those figures was presented in [Supplementary Information](#SD1){ref-type="supplementary-material"}*). Additionally, high expressionlevelof Flotillin-1 was also found to be significantly associated with lymph node metastasis (OR =6.30; 95% CI:3.15-12.59, p\<0.001), distant metastasis (OR =6.02; 95% CI: 1.50-24.06, p=0.01) and more advanced TNM stage (OR =4.69; 95% CI: 2.74-8.03, p\<0.001). However, gender was not significantly related to Flotillin-1 expression. Owing to insufficient data, we failed to detect the relationship between high Flotillin-1 expression and other clinicopathological features.

###### Meta-analysis results of the associations of high Flotillin-1 protein expression level with multiple clinicopathological parameters

  Clinicopathological parameter                Studies (n)   Number of patients   OR (95% CI)        p-value   Heterogeneity           
  -------------------------------------------- ------------- -------------------- ------------------ --------- --------------- ------- ----------------
  Sex(male vs. female)                         7             1326                 0.94(0.73-1.20)    0.61      0               3.45    Fixed effects
  Histological grade(poor/moderate vs. well)   7             1542                 2.22(1.04-4.78)    0.04      85              39.72   Random effects
  T classification (T~3-4~ vs. T~1-2~)         5             1054                 2.73(1.44-5.17)    0.002     69              12.98   Random effects
  Lymph node metastasis(yes vs. no)            7             1468                 6.30(3.15-12.59)   \<0.001   84              38.67   Random effects
  Distant metastasis (yes vs. no)              3             801                  6.02(1.50-24.06)   0.01      68              6.16    Random effects
  TNM stage(III-IV vs. I-II)                   8             1538                 4.69(2.74-8.03)    \<0.001   75              27.58   Random effects

Sensitivity analysis {#s2_7}
--------------------

For the association between Flotillin-1 expression level and OS, sensitivity analysis was performed by sequentially omitting each study from the pooled analysis. When any individual study was discarded, the pooled HRs was not significantly changed, suggesting that the results were stable and reliable (Figure [7](#F7){ref-type="fig"}).

![Results of sensitivity analysis for OS](oncotarget-08-52665-g007){#F7}

Publication bias {#s2_8}
----------------

For the meta-analysis of the association between Flotillin-1 expression levels and OS, Begg\'s funnel plots and Egger\'s test were applied to assess publication bias. Begg\'s funnel plot (Figure [8](#F8){ref-type="fig"}) showed that there was no significant publication bias observed among those studies (Pr \> \|z\| = 0.139, z = 1.48). While the p-value of Egger\'s test exhibited a slight publication bias among studies (p= 0.011). And then, the trim and fill method was applied to test for publication bias. The results suggested there was no significant publication bias across-studies. Because of the limited number of included studies (n\<10), the publication biases for DFS, RFS, PFS and clinicopathological parameters were not assessed.

![Begg\'s funnel plot of Flotillin-1 expression and OS](oncotarget-08-52665-g008){#F8}

DISCUSSION {#s3}
==========

Flotillin-1 was generally over-expressed in breast cancer, colorectal cancer, liver cancer, esophageal squamous cell carcinoma \[[@R22]--[@R25]\] and so on. A new study indicated that Flotillin-1 expression was upregulated significantly in transitional cell carcinomas(TCCs) compared to normal urothelial tissue, moreover, Flotillin-1 expression was significantly associated with tumor size, pathologic grade, clinical stage and recurrence based on t-tests \[[@R26]\]. These findings suggested that Flotillin-1 could be a new target for future cancer immunotherapy. Although Flotillin-1 have been discovered for many years, the function of it in carcinogenesis is not fully clear. According to the review of relevant publications, Flotillin-1 has participated and regulated the tumor development processes with multiple pathways.

Flotillin-1 was critical regulator in receptor tyrosine kinase(RTKs) pathway. Flotillin-1 was involved in signaling processes of RTKs, such as lgE receptor, EGRF and insulin \[[@R27]--[@R30]\]. Flotillin-1 could activate EGFR signal pathways by recruiting receptor kinases to lipid rafts \[[@R17]\]. Researchers found that knockdown of Flotillin-1 in MCF7 cells resulted in upregulation of EGFR mRNA and protein expression \[[@R31]\]. Flotillin-1 has made effects with Akt/FOXO3a pathways in breast cancer. The silencing Flotillin-1 would reduce the activity of Akt and then enhance the activity of FOXO3a. Thus, upregulation of cyclin-dependent kinase inhibitor p21(Cip1) and p27(Kip1), and downregulation of the CDK regulator cyclin D1, the proliferation and tumorigenesis of breast cancer cells would be inhibited \[[@R32]\]. Flotillin-1 has participated in the activation of NF-κB pathways. In esophageal squamous cell carcinoma, Flotillin-1 facilitated recruitment of the tumor necrosis factor-α receptor to lipid rafts; promoted K63-linked polyubiquitination of the signaling intermediaries tumor necrosis factor receptor associated factor 2, receptor interacting protein and NEMO; and sustained the activation of NF-κB. Levels of FLOT1 correlated with activation of NF-κB in ESCC samples from patients \[[@R33]\]. These findings suggested that Flotillin-1 would be a key target in integrative tumor development system.

The determination method of Flotillin-1 protein expression would be critical if it would be applied as a prognostic marker. The method for characterizing Flotillin-1 protein expression would be standardized, following factors should be considered. Firstly, the determination method for biomarkers should be unified, no matter IHC, IFA or ELISA. For Flotillin-1 in solid tumor, the IHC was the most common and robust method for its characterization. Secondly, the reagents and controls should be stable and commercially available. The reagents should be provided as kit, including the primary antibody, 2^nd^ antibody and developer. The controls should be also stable for quality control. The cut-off value should be determined per the instruction of the kit. Thirdly, a standard manipulation procedures should be established, such as consistent sample processing, incubation time etc. In addition, automatic device should be involved for more stable results. Specifically, the unified criteria should be verified with a well-designed, large-scale, multi-center case-control study. The result should be further evaluated, including the significance, correlation, corrected cutoff values.

Our meta-analysis provided strong evidence that high Flotillin-1 protein expression was statistically significant associated with shorter OS in patients with solid tumors. The subgroup analysesshowed that the negative effect of elevated Flotillin-1 on OS was revealed in patients with RCC, LC and digestive system cancers. Furthermore, the present meta-analysis suggested that cancer patients with elevated level of Flotillin-1 have a significantly poorer DFS, RFS and potential worse PFS. Our meta-analysis also suggested that flotillin-1 expression level was related to histological grade and depth of primary tumor invasion. Additionally, high expression of Flotillin-1 was also found to be significantly associated with metastasis and more advanced TNM stage. However, gender was not significantly related to Flotillin-1 expression. Our results indicated an important role for Flotillin-1 in the development and progression of tumor, the precise mechanisms of its effects have been demonstrated, however, it should be proved with further well-designed clinical studies.

As we know, this is the first meta-analysis providing precise evidence that elevated expression level of Flotillin-1 protein would be significantly correlated with poor clinical outcomes in patients with solid tumors. However, there are still some limitations in our meta-analysis. First, only 13 studies were included in this study, which resulted in relatively insufficiency data in the subgroup analyses. Especially, only two studies were included in the relationship between Flotillin-1and RFS, PFS. The credibility of results would be reduced. Second, patients included in the meta-analysis were mostly Asians from P. R. China, researches from other countries and races were relatively less. Additionally, publication bias may exist, even though no significant publication bias was observed based on the trim and fill method, as well as stable results were revealed in sensitivity analysis. Finally, different measuring method and cut-off values were applied in those studies, which may affect the availability of Flotillin-1 as a predictive biomarker in cancer prognosis. In view of this situation, further studies with larger sample size are still needed to identify the most appropriate measuring method and cut-off value.

In conclusion, our results clearly suggested that flotillin-1 could be applied for improving prognosis estimation of solid tumors. Considering the limitations of present analysis, this conclusion should be regarded cautiously. Further prospective large-scale, multi-center case-control studies designed adequately with larger sample size are needed to confirm the prognosis value of Flotillin-1 in cancer patients, as well as to explore the function mechanism for guiding effective therapy strategies.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

For obtaining potentially eligible studies, a comprehensive literature retrieval was conducted in PubMed, Web of Science, Embase, and CNKI, with a cut-off date of Nov. 10, 2016. Only the results from articles in English or Chinese were included. The keywords for the search were as follows: "Flotillin-1", "reggie-2", "FLOT-1", "cancer", "carcinoma", "neoplasm" and "tumor". In addition, the references of other relevant articles were also manually reviewed.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria for the articles were as follows: (1) the role of Flotillin-1 in the development of human cancer was investigated; (2) associations of Flotillin-1 protein expression with prognosis or clinicopathological features were described; (3) the expression levels of Flotillin-1 protein in primary cancerous tissue were measured; (4) patients were divided into high and low expression groups according to the expression level of Flotillin-1protein; and (5) the articles were written in English or Chinese.

Exclusion criteria for the articles were as follows: (1) duplicate publications; (2) studies without available or usable data; and (3) reviews, letters, case reports and expert opinions.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators (Ou YX and Liu FT) independently extracted data and information from the included studies. For any disagreements, the consensus was reached by group discussion. The following data and information were retrieved from each publication: the name of first author, the year of publication, original country, cancer type, number of patients, tumor stage, follow-up period, outcome measures, the criteria for high Flotillin-1 expression, assay methods and hazard ratio (HR) as well as corresponding 95% confidence interval (CI). Besides, the data of clinicopathological parameters were also extracted from the eligible studies. The Newcastle-Ottawa Scale (NOS) was applied to assess the quality of all included studies. The NOS scores ranged from 0 to 9, and the study with an NOS score ≥ 6 was considered to be of high quality. The quality of all studies included in this meta-analysis varied from 6 to 8, with a mean valueof 6.8.

Flotillin-1 determination {#s4_4}
-------------------------

The level of Flotillin-1 protein was determined based on immunoassay. The Flotillin-1 was detected with immunohistochemistry(IHC) in most included studies and it was detected with Western blot(WB) in only one study. For IHC, the staining index score (SI) and immunoreactivity score (IRS) were applied for evaluating the Flotillin-1 level. For WB, the intensity of protein stripe was compared to that of in control protein. For Flotillin-1 assay, the reagents were different with different interpretation criteria. There was also no consensus of cutoff value for determining the high and low expression level of Flotillin-1. In individual study, the cutoff value of Flotillin-1 expression level was determined per their own rules, either based on the instruction of use of reagents manufacturer or clinical experience or existing publications. However, the results in individual study could be comparable for the consistent conditions.

Statistical methods {#s4_5}
-------------------

Statistical analyses of HRs for prognostic value was calculated by Stata SE12.0 (StataCorp, College Station, TX), and the ORs(odds ratios) for clinical pathological parameters was calculated through RevMan5.3 software. Heterogeneity of pooled results was assessed with Cochrane\'s Q test and I^2^ measurement. A P value for Q test exceeding 0.05 and/or I^2^ value less than 50 % were considered as no severe heterogeneity, then the fixed effects model was applied; otherwise the random-effects model would be used (P~*h*~≤0.05, I^2^≥50%). Sensitivity analysis was performed to evaluate the validity and reliability of the meta-analysis. Begg\'s funnel plot and Egger\'s test were applied to evaluate the publication bias risk. The p-value of less than 0.05 was defined as statistically significant. For studies with both the results of univariate and multivariate analysis, only the latter was selected because of its higher precision as accounting for confounding factors. If a study reported only Kaplan-Meier curves, Engauge Digitizer version 4.1 (<http://digitizer.sourceforge.net/>, a free down-loaded software) was involved to extract the survival data.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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